ALX Oncology receives Nasdaq bid price non-compliance notice; 180-day cure until Oct 20, 2025

ALX ONCOLOGY HOLDINGS INC

Nasdaq notified ALXO on Apr 23, 2025 that its common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.
Company has until Oct 20, 2025 to regain compliance by closing at or above $1.00 for at least ten consecutive business days.
If not cured, ALXO may seek a second 180-day period by transferring to the Nasdaq Capital Market, subject to eligibility.
Potential cure actions include a reverse stock split; failure to regain compliance could lead to delisting.
ALXO intends to actively monitor bid price and assess options, but no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.